Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Treatment Study of Germline BRCA 1/2 Mutation Patients with Early Triple Negative Breast Cancer
The purpose of the study is to determine if the study drug talazoparib is safe when given as a neoadjuvant (a first step to shrink a tumor before the main treatment) breast cancer treatment for germline BRCA 1/2 invasive triple-negative breast cancer, and to evaluate how the tumor responds to the drug.
In order to participate you must meet the following criteria:
- Are at least 18 years of age at enrollment.
- Have germline BRCA 1/2 mutation positive, invasive triple-negative breast cancer.
- Have no evidence of distant metastasis.
- Have adequate bone marrow, hepatic and renal function.
You will be excluded from the study if any of the following criteria apply to you:
- Have any other previous antitumor therapies for the current cancer event. Treatment for ductal carcinoma in situ (DCIS) is allowed.
- Have inflammatory breast carcinoma.
- Have had previous or concomitant systemic anti-cancer therapies used for the treatment of cancer in the last 3 years.
This is a partial list of inclusion and exclusion criteria.